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hyperhomocysteinemia (hhcy) is a well-known risk factor of cardiovascular diseases, 
however, the mechanism of its detrimental effect is incompletely understood. some 
studies suggest that, paradoxically, hhcy may promote traditional risk factors such as 
hyperlipidemia. We examined the effect of experimental hhcy on plasma lipid profile, 
glucose and insulin concentrations as well as on high-density lipoprotein (hDl)-associ-
ated antiatherosclerotic enzyme, paraoxonase 1 (pOn1). hyperhomocysteinemia was 
induced by feeding male Wistar rats with diet enriched with methionine or diet en-
riched in methionine and deficient in folate, vitamin b6 and b12 for 8 weeks. These diets 
resulted in the 3.3- and 9.6-fold elevation of plasma hcy, respectively. plasma total and 
hDl-cholesterol, triglycerides and apolipoprotein a-I were similar in all groups. high-
methionine diets had no effect on fasting plasma glucose but significantly increased 
fasting plasma insulin concentration indicating impaired ability of insulin to suppress 
hepatic glucose output. pOn1 activity was unchanged in high methionine vitamin b-
sufficient diet-fed rats, but was decreased by 30-40% toward various substrates in high 
methionine vitamin b-deficient diet-fed animals. The results indicate that hhcy has no 
effect on lipid metabolism, however, induces insulin resistance and, above certain hcy 
level, pOn1 deficiency. Impaired insulin signaling and reduced pOn1 activity may con-
tribute to detrimental effects of hhcy.
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introduction
Homocysteine (Hcy) is a non-
protein aminoacid which is syn-
thesized from dietary methionine 
through S-adenosylmethionine and 
S-adenosylhomocysteine as interme-
diates, and is metabolized by  either 
remethylation to methionine by me-
thionine synthase or by transsulfu-
ration to cysteine by cystathionine 
β-synthase (CBS) and cystathionine 
γ-lyase (CSE) (1). Hcy metabolism 
is dependent on the availability of 
folate (its derivative, 5-methyltet-
rahydrofolate, donates methyl groups 
for Hcy remethylation), vitamin B12 
(a cofactor of 5-methyltetrahydro-
folate synthesis) and vitamin B6 (a 
cofactor of both CBS and CSE) (2). 
Normal plasma Hcy concentration is 
about 5-15 μM. Many clinical studies 
have demonstrated that hyperhomo-
cysteinemia (hHcy) is an independ-
ent risk factor of atherosclerosis and 
thrombosis. In addition, hyperhomo-
cysteinemia is involved in the patho-
genesis of many other disorders in-
cluding glomerulopathy, Alzheimer 
disease, neural tube defects and os-
teoporosis. Hyperhomocysteinemia 
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may be responsible for high risk of cardiovascular diseases in 
many patients without classical atherosclerosis risk factors (e.g. 
those with normal blood pressure, normolipidemia and normo-
glycemia) as well as for the residual risk in patients treated with 
anti-classical risk factor therapies such as cholesterol-lowering 
statins, antidabetic and antihypertensive medications. The most 
important causes of hyperhomocysteinemia are genetic defects 
of Hcy-metabolizing enzymes such as CBS or methylenetetrahy-
drofolate reductase (MTHFR), high methionine intake (e.g. diet 
rich in meat), deficiency of folate, vitamin B6 and B12, metabolic 
syndrome and renal dysfunction. In addition, hyperhomocyst-
einemia may be induced or aggravated by certain drugs includ-
ing those used to prevent cardiovascular diseases such as fibrates 
(2).
Although proatherogenic effect of hHcy is well established, 
the mechanism of detrimental impact of homocysteine is un-
clear. Several effects of Hcy have been described such as unben-
eficial shift of coagulation/fibrinolysis balance, hypertrophy of 
vascular smooth muscle cells, induction of vascular inflamma-
tion, oxidative stress and depletion of vascular nitric oxide (3). 
However, most of these effects were observed using high, supra-
physiological or even “suprapathological” concentrations of Hcy 
such as 1-10 mM, whereas plasma Hcy level even in severe hHcy 
rarely exceeds 200 μM. Therefore, the molecular target for Hcy 
is still searched for.
Several studies have demonstrated that hHcy may have a det-
rimental effect on plasma lipid profile. However, these studies 
are either observational clinical correlation studies which can-
not imply the cause-effect relationship, or experiments in specif-
ic animal models such as CBS knockout mice or hHcy induced 
by very high methionine intake, which may have effects inde-
pendent of Hcy elevation. In addition, insulin resistance and 
metabolic syndrome are well established risk factors of athero-
sclerosis. The association between hHcy and insulin resistance/
metabolic syndrome has been observed, but it is unclear if in-
sulin resistance results in hyperhomocysteinemia or, vice versa, 
homocysteine impairs insulin signaling. In the present study we 
examined the effect of hHcy induced in the rat by moderate in-
crease in methionine intake on plasma lipid profile as well as on 
glucose and insulin concentrations. In addition, we measured 
plasma paraoxonase 1 (PON1) activity. PON1 is a high-density 
lipoprotein (HDL)-associated atheroprotective enzyme which 
decomposes lipid peroxidation products as well as homocyst-
eine thiolactone – the toxic endogenous Hcy derivative (4). 
Atherosclerosis is aggravated and reduced in PON1 knockout 
and PON1-overexpressing mice, respectively and low PON1 is 
a risk factor of cardiovascular events in humans. Changes in 
plasma lipid profile, especially low HDL, is often associated with 
PON1 deficiency (4). Therefore, it is of interest if hHcy affect 
PON1 status.
materials and methods
The study was performed on adult male Wistar rats weighing 264 
± 6 g before the experiment. We used the experimental model of 
hHcy described by De Vriese et al (5). After 2-week acclimation, 
animals were randomized to three experimental groups (n=8 
each): (1) control, fed standard rodent chaw (2) high-methio-
nine diet (Harlan Teklad TD98002), (3) high-methionine diet 
deficient in folate, vitamin B6 and B12 (Harlan Teklad TD97345). 
Except methionine and vitamins, the content of other nutrients 
was identical in all diets. The composition of diets is presented 
in Table 1. The respective diets were administered for 8 weeks.









methionine (g/kg) 3.8 7.7 7.7
Folic acid (g/kg) 0.002 0.002 –
vitamin b6 (g/kg) 0.07 0.07 –
vitamin b12 (g/kg) 0.00003 0.00003 –
choline (g/kg) 2.5 2.5 2.5
Blood for biochemical studies was withdrawn after the 
6-hour fasting. Rats were anesthetized with thiopental (50 mg/
kg ip.) and blood was withdrawn from the abdominal aorta into 
heparinized tubes (for PON1 assay) and EDTA-containing tubes 
(for the remaining assays). Plasma was separated by centrifuga-
tion at 3000 rpm for 10 min at 4oC, frozen and stored at -80oC 
until analysis.
Total plasma Hcy was measured by enzyme immunoassay 
using kit purchased from Axis Shield Diagnostics (Dundee, 
UK). Since most of the plasma Hcy occurs in the form of di-
sulfides, samples were first reduced with dithiothreitol (DTT) 
to convert Hcy to a free thiol form. Hcy is then converted to 
S-adenosylhomocysteine (SAH) by adding the excess of adeno-
sine and SAH hydrolase, and the latter is assayed using specific 
anti-SAH antibodies (6). PON1 activity toward synthetic (par-
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aoxon and phenyl acetate) as well as natural substrate (homo-
cysteine thiolactone) was measured as described previously (6).
Total plasma cholesterol, HDL-cholesterol, triglycerides and 
glucose were measured spectrophotometrically using com-
mercially available kits (AlphaDiagnostics, Warsaw, Poland). 
Alanine and aspartate aminotransferase (ALT and AST) activi-
ties were measured using Sigma-Aldrich kits and are expressed 
in Sigma-Frankel units/ml. Insulin and apolipoprotein A-I con-
centrations were measured by enzyme-linked immunoassay us-
ing kits specific for rat proteins (Mercodia, Uppsala, Sweden and 
Uscnlife, East Lack, China, respectively); insulin concentration 
calculated from standard curve in μg/l was expressed in μU/ml 
assuming WHO definition: 1 mg = 26 U. Plasma non-esterified 
fatty acids (NEFA) and glycerol were measured by spectrofluo-
rometric and spectrophotometric methods, respectively, us-
ing Cayman Chemical kits. For details of these methods, see 
(7). Homeostatic Model Assessment-Insulin Resistance Index 
(HOMA-IR) was calculated as: I×G/22.5, where I is fasting plas-
ma insulin in μU/ml and G is fasting plasma glucose in mM. 
Quantitative Insulin Sensitivity Check Index (QUICKI) was cal-
culated as 1/[log(G) + log(I)], where G is fasting plasma glucose 
in mg/dl and I is fasting plasma insulin in μU/ml. HOMA-IR 
and QUICKI, derived from fasting plasma insulin and glucose, 
reflect mainly the ability of insulin to suppress hepatic glucose 
output (8). 
Results are expressed as mean ± SEM from 8 animals in each 
group. Statistical analysis was performed by one-way ANOVA 
followed by Tukey post-hoc test. A p value <0.05 was considered 
significant.
results
Administration of methionine-rich or methionine-rich vitamin 
B deficient diets had no effect on food intake (not shown) and 
weight gain of the animals (Table 2). Plasma Hcy concentra-
tion was higher (p<0.001) in high methionine-rich diet fed rats 
(26.4 ± 2.5 μM) than in control animals (7.9 ± 0.5 μM). In group 
receiving high-methionine vitamin B-deficient diet plasma 
Hcy was 76.1 ± 9.3 μM, i.e. significantly higher than in control 
(p<0.001) and methionine-rich diet fed rats (p<0.05).
Plasma concentrations of triglycerides, total cholesterol, 
HDL-cholesterol and apolipoprotein A-I were not different 
between groups.  In addition, hHcy induced by either diet had 
no effect on alanine and aspartate aminotransferase activities 
(Table 2).
Plasma glucose concentration was similar in all groups. In 
contrast, both methionine-rich diets increased fasting plasma 
insulin concentration. However, insulin concentration did not 
differ between methionine-fed groups with different vitamin 
B content (Table 3). Consequently, HOMA-index, a marker of 
insulin resistance, was higher in methionine-enriched and me-
thionine-enriched vitamin B-deficient diet fed rats by 73.6% and 
91.9%, respectively; the difference between both hHcy groups 
being non-significant. On the contrary, quantitative insulin sen-
sitivity check index was lower in rats fed methionine-enriched 
and methionine-enriched vitamin B-deficient diets by 6.6% and 
7.9%, respectively (Table 3). Plasma concentrations of glycerol 
and non-esterified fatty acids were not different between groups 
(Table 3).
Plasma PON1 activity in rats fed methionine-enriched diet 
table 2. Effect of hyperhomocysteinemia on body weight, plasma lipids and liver enzymes
Group Control High methionine
High methionine 
vitamin B deficient
body weight (g) 345 ± 11 352 ± 9 368 ± 11
Triglycerides (mm) 0.63 ± 0.07 0.61 ± 0.06 0.69 ± 0.08
Total cholesterol (mm) 1.64 ± 0.19 1.71 ± 0.20 1.76 ± 0.17
hDl-cholesterol (mm) 0.77 ± 0.07 0.83 ± 0.08 0.79 ± 0.06
apolipoprotein a-I (mg/dl) 65.3 ± 5.7 62.4 ± 6.1 59.3 ± 5.8
alT (u/ml) 18.4 ± 1.4 16.2 ± 1.4 18.1 ± 1.0
asT (u/ml) 22.0 ± 1.7 21.3 ± 2.1 23.5 ± 1.6
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did not differ from control. In contrast, PON1 activity toward 
paraoxon, phenyl acetate and Hcy thiolactone was lower in ani-
mals receiving methionine-enriched vitamin B-deficient diet 
than in control group by 30.3%, 32.1% and 42.5%, respectively 
(Table 4).
Discussion
That hHcy may have a detrimental effect on lipid metabolism 
was first proposed by Werstuck et al (9) who have demonstrated 
that high Hcy concentrations (1-5 mM) activate sterol regula-
tory element-binding proteins-1 and -2 (SREBP-1 and -2) in cul-
tured hepatoma cells. SREBP-1 and SREBP-2 are transcription 
factors which stimulate the expression of enzymes involved in 
fatty acid and cholesterol synthesis, respectively. Consequently, 
Hcy increased the expression of a rate-limiting enzyme in cho-
lesterol synthesis, 3-hydroxy-3-methylglutarylcoenzyme A 
(HMG-CoA) reductase, as well as of several more distal enzymes 
in this pathway such as isopentelypyrophosphate isomerase and 
farnesylpyrophosphate synthetase. Moreover, Hcy increased the 
expression of lipogenic enzymes, acetyl-CoA carboxylase and 
fatty acid synthase. In vivo, plasma cholesterol concentration 
and hepatic VLDL secretion were higher in hHcy CBS knock-
out mice (9). In subsequent study (10) hypertriglyceridemia, 
increased plasma VLDL and apolipoprotein-B100 were also 
observed in CBS knockout mice. In the rat, administration of 
methionine in the drinking water for 4 weeks increased hepatic 
SREBP-2 and HMG-CoA reductase as well as plasma and liver 
cholesterol concentrations by about 20% (11).
In the present study plasma cholesterol and triglycerides did 
not change in hHcy rats which most likely results from different 
experimental model. In contrast to CBS knockout mice, plasma 
Hcy is less markedly elevated in our methionine-fed rats; the 
model which better reflects mild-to-moderate hHcy in humans. 
In addition, CBS knockout mice suffer from liver steatosis and 
table 4. Effect of hyperhomocysteinemia on pOn1 activity toward different substrates
Group Control High methionine
High methionine 
vitamin B deficient
paraoxon (u/ml) 157 ± 8 149 ± 7 109,4 ± 8***
phenyl acetate (u/ml) 124 ± 9 119 ± 6 84,2 ± 7***
homocysteine thiolactone (nmol/min/ml) 220 ± 18 207 ± 17 127 ± 11***
***p<0.001 versus control group.
table 3. Effect of hyperhomocysteinemia on markers of carbohydrate metabolism and lipolysis
Group Control High methionine
High methionine  
vitamin B deficient
glucose (mm) 5.1 ± 0.2 5.3 ± 0.3 5.4 ± 0.2
Insulin (μu/ml) 21.4 ± 2.5 35.6 ± 3.6** 38.8 ± 3.2***
hOma-IR 4.85 ± 0.41 8.42 ± 0.91*** 9.31 ± 1.11***
QuIckI 0.303 ± 0.003 0.283 ± 0.003** 0.279 ± 0.002***
nEFa (μm) 372 ± 21 369 ± 28 383 ± 31
glycerol (μm) 198 ± 13 191 ± 17 195 ± 16
hOma-IR, homeostatic model assessment-insulin resistance index, QuIckI, quantitative insulin sensitivity check index, nEFa, 
non-esterified fatty acids. **p<0.001, ***p<0.001 vs. control group.
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dysfunction which was not observed in methionine-fed rats as 
evidenced by normal activity of liver enzymes. In many stud-
ies in which hHcy was induced by methionine-enriched diets, 
high methionine doses (up to 1.5-2% in chow or drinking water) 
were applied; such doses may also lead to liver damage (12-14). 
In addition, methionine feeding may affect lipid profile inde-
pendently of Hcy. Indeed, methionine provides methyl groups 
for phosphatidylethanolamine N-methyltransferase which con-
verts phosphatidylethanolamine to phosphatidylcholine result-
ing in the increase in VLDL secretion from the liver (15). In ac-
cordance with our results, lower methionine doses (<1%) had no 
effect on plasma total cholesterol, LDL-cholesterol or triglycer-
ides in Sprague-Dawley rats (16,17). Similarly, addition of 0.5% 
methionine in the drinking water did not change plasma lipid 
profile in mice fed normal, “western-type” or atherogenic diet 
(18). Moreover, hHcy induced by administration of Hcy thiol-
actone, i.e. not associated with methionine excess, had no effect 
on plasma lipid profile, cholesterol concentration in the liver, 
SREBP-2 activity, HMG-CoA reductase or LDL receptor in the 
rat (19). Taken together, these data suggest that although specific 
forms of hHcy (genetically determined severe hHcy, very high 
methionine intake) may affect plasma lipid metabolism, mild-
to-moderate hHcy has no effect.
Another concern is the link between Hcy and HDL and its 
integral apolipoprotein, apo A-I. Hcy (5 mM) inhibited apo A-I 
synthesis in human hepatoma HepG2 cells (20) and in mouse 
primary hepatocytes (21). Plasma apo A-I and HDL cholesterol 
are reduced in heterozygous MTHFR deficient mice (20,22), in 
CBS knockout mice (23), in apo-E/CBS double knockout mice 
in comparison to CBS+/+ apo-E-/- mice (21) and in homozygous 
CBS-deficient humans (23). In addition, negative correlation be-
tween HDL cholesterol/apo A-I and serum Hcy was observed 
in patients with ischemic heart disease (20,24). However, in the 
present study HDL cholesterol and apo A-I were normal in both 
hyperhomocysteinemic groups. This may be due to (i) lower 
Hcy concentration than in CBS deficiency, and (ii) species dif-
ferences – Hcy decreases apo A-I synthesis in human hepato-
cytes by suppressing the activity of peroxisome proliferator-ac-
tivated receptor-α (PPAR-α) which stimulates apo A-I synthesis 
in humans but not in rodents (25).
We demonstrated that hHcy had no effect on fasting plasma 
glucose but significantly increased plasma insulin and HOMA 
index to the similar extent in both groups. These data indicate 
that (i) even modest Hcy elevation has a detrimental effect on 
insulin sensitivity and this effect is not dependent on Hcy con-
centration, and (ii) impaired insulin sensitivity results from 
high methionine intake/Hcy elevation rather than from vitamin 
B deficiency. During fasting state, the main metabolic effect of 
insulin is suppression of hepatic gluconeogenesis and glucose 
output. When the liver becomes insulin-resistant, pancreatic 
β cells produce more insulin to sustain normoglycemia. Thus, 
increase in fasting insulin level is the evidence of hepatic insu-
lin resistance (8). In addition, during fasting state insulin sup-
presses lipolysis in white adipose tissue. However, markers of 
lipolysis, NEFA and glycerol concentrations, were unchanged 
in this study, indicating that insulin sensitivity of the liver but 
not of adipose tissue was reduced. Previously, hHcy induced 
by Hcy administration has been demonstrated to increase fast-
ing insulin in rats (26) and mice (27). In contrast, feeding mice 
with high-methionine diet for 3 months has no effect on fast-
ing insulin and glucose as well as on glucose tolerance, but in-
sulin secretion during oral glucose tolerance test was elevated, 
suggesting post-prandial (decrease in insulin-induced glucose 
disposal) rather than fasting insulin resistance (28). However, 
in the same study, pretreatment of primary mouse hepatocytes 
with 0.1 mM Hcy for 6 hours abolished suppressing effect of in-
sulin on glucose output, which supports our results. Moreover, 
the expression of a rate-limiting enzyme of gluconeogenesis, 
phosphoenolpyruvate carboxykinase (PEPCK), was higher in 
hyperhomocysteinemic mice at both mRNA and protein level 
(28). In vitro, Hcy increased PEPCK expression in mouse hepat-
ocytes, and inhibitor of protein kinase A abolished the effect of 
Hcy on PEPCK expression and insulin-induced inhibition of 
glucose output. These data indicate that hHcy impairs the effect 
of insulin on hepatic gluconeogenesis. Moreover, Hcy thiolac-
tone inhibits the effect of insulin on tyrosine phosphorylation 
of insulin receptor substrate-1 in cultured human hepatocytes 
(29). Apart from direct effect on hepatocytes, hHcy may impair 
insulin sensitivity by modifying adipokines production. For ex-
ample, hHcy has been demonstrated to stimulate resistin (27) 
and inhibit adiponectin (30) secretion. The mechanism of insu-
lin resistance induced by hHcy in the present study remains to 
be established.
PON1 is synthesized in the liver and circulates attached to 
plasma HDL. Lipid composition of HDL as well as its integral 
apolipoprotein, apo A-I, are essential for PON1 transfer from 
hepatocytes to lipoproteins and its stability and activity. The in-
verse correlation between Hcy concentration and PON1 activity 
was reported in clinical studies (31-34). In addition, PON1 ex-
pression in the liver is increased in patients with Down syndrome 
who have high CBS level (the cbs gene is located on chromosome 
21) and low plasma Hcy (35). Hepatic PON1 expression and ac-
tivity are dramatically reduced in homozygous CBS knockout 
mice (36,37), however, this effect most likely results from liver 
dysfunction and/or HDL and apo A-I deficiency. CBS knockout 
mice with transient transgenic expression of the human enzyme, 
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in which Hcy concentration is comparable to CBS knockout 
animals but liver function is intact, exhibit normal PON1 activ-
ity toward paraoxon and only slightly reduced (-17%) activity 
toward phenyl acetate (23). In untreated or poorly compliant 
CBS deficient patients (plasma Hcy 160-310 μM) PON1 activity 
toward paraoxon did not differ from normohomocysteinemic 
healthy subjects, but its activity toward phenyl acetate was by 
30% lower (23). These data suggested that hHcy has little effect 
on PON1 in the absence of liver dysfunction.
However, PON1 expression in the liver is also reduced in het-
erozygous CBS+/- mice fed a high-methionine diet (but not in 
CBS+/- mice fed a regular diet), in which liver function is not im-
paired (37). The polyphenolic compound, catechin (38), as well 
as red wine polyphenols (39) reduced plasma Hcy concentra-
tion and increased PON1 expression in the liver of heterozygous 
CBS+/- mice fed a high-methionine diet, whereas another poly-
phenol, quercetin, had no effect on either Hcy or PON1 (38). 
Surprisingly, one of the most prevalent polyphenol of the red 
wine, resveratrol, administered alone, increased plasma Hcy and 
further reduced PON1 expression and activity in methionine-
fed CBS+/- mice (40). Ferretti et al (41,42) have demonstrated 
that incubation of HDL isolated from healthy normolipidemic 
subjects with Hcy thiolactone decreases PON1 activity. Clinical 
studies have indicated that mild hHcy (~20 μM) has no effect 
on PON1 status but more sever hHcy (~70 μM) is associated 
with PON1 deficiency (43). We demonstrated that high-me-
thionine vitamin B-deficient but not high-methionine vitamin 
B-sufficient diet results in the deficiency of plasma PON1 despite 
normal HDL and apo A-I levels. Together with clinical observa-
tions (43) and studies in mice with different Hcy concentrations 
(44), these results indicate that PON1 activity decreases above 
certain Hcy level even if liver function, HDL concentration and 
apo A-I are normal. If this effect results from direct inhibition 
of plasma PON1 by Hcy (42) or other mechanisms such as spe-
cific suppression of enzyme synthesis in the liver, remains to be 
established.
In conclusion, we have demonstrated that hHcy induced 
in the rat by high-methionie or high-methionine vitamin 
B-deficient diets has no effect on plasma lipid concentration as 
well as on apolipoprotein A-I. Both high-methionine diets in-
creased fasting plasma insulin suggesting impaired effect of this 
hormone on hepatic glucose output. Hyperhomocysteinemia 
had no effect on non-esterified fatty acids or glycerol indicating 
that antilipolytic effect of insulin was intact. Plasma PON1 activ-
ity was normal in high-methionine fed group but was reduced in 
high-methionine vitamin B-deficient group. Decrease in insulin 
sensitivity and PON1 deficiency may contribute to detrimental 
effects of hHcy on cardiovascular system.
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